Maria J Faus


Affiliation: University of Granada
Country: Spain


  1. Pérez Ramírez C, Cañadas Garre M, Alnatsha A, Villar E, Delgado J, Faus Dáder M, et al. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients. Pharmacol Res. 2016;111:877-884 pubmed publisher
    ..In conclusion, ERCC1 C118T, ERCC2 rs50872, ERCC2 Asp312Asn, ABCB1 C1236T, IL1B rs12621220 and IL16 rs7170924 polymorphisms may substantially act as prognostic factors in NSCLC patients treated with platinum-based chemotherapy. ..
  2. Pérez Ramírez C, Cañadas Garre M, Molina M, Robles A, Faus Dáder M, Calleja Hernández M. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer. Mutat Res. 2017;771:32-58 pubmed publisher
    ..Some polymorphisms have been reported to be associated with toxicity or clinical outcome, but data generally come from a limited number of studies and need to be confirmed. ..
  3. Pérez Ramírez C, Cañadas Garre M, Alnatsha A, Molina M, Robles A, Villar E, et al. Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer. Surg Oncol. 2017;26:278-285 pubmed publisher
    ..No influence of IL1B rs12621220, IL1B rs1143623, IL1B rs16944, IL1B rs1143627, IL6 rs1800795, IL13 rs1881457 on NSCLC clinical outcomes was found in our patients. ..
  4. Pérez Ramírez C, Cañadas Garre M, Alnatsha A, Villar E, Delgado J, Calleja Hernández M, et al. Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer. Pathol Res Pract. 2018;214:44-52 pubmed publisher